The company intends to use the funds to finance its registration program for the natriuretic peptide Ularitide in acute heart failure.
Led by Johannes Holzmeister, M.D., Chief Executive Officer and Chief Medical Officer, Cardiorentis has developed a disease-based technology platform that integrates expertise in protein biology to identify novel targets and rationally design small molecule compounds and peptides.
Ularitide is a natriuretic peptide in Phase III development as an intravenous (IV) infusion treatment for acute heart failure (AHF) limited by United States law to investigational use only. It is the chemically synthesized form of urodilatin – a human, natriuretic peptide that is produced in the kidneys and induces excretion of sodium into the urine (natriuresis) and increased urine production (diuresis) to regulate fluid balance and sodium haemostasis. The peptide induces natriuresis and diuresis by binding to specific natriuretic peptide receptors (NPR-A, NPR-B and other natriuretic peptide receptors), thereby increasing intracellular cyclic guanosine monophosphate (cGMP) relaxing smooth muscle tissues, leading to vasodilation and increased blood flow.